米非司酮联合宫瘤消胶囊治疗子宫肌瘤的临床研究

摘要

Objective To investigate the clinical effect of mifepristone combined with gongliuxiao in treatment of uterinefibroids.Methods 60 cases of patients with uterinefibroids were randomly divided into study group and control group,30 cases in each group.The research group was treated with mifepristone combined with uterine tumor,while the control group was treated with mifepristone alone.3 months after treatment,the clinical efficacy and adverse reactions between the two groups were compared.Results After treatment,the volume of uterus(13.21±5.38)cm3and myoma (1.50±1.21)cm3of the study group were significantly smaller than those of the control group (t=4.987,3.388,P<0.05).The total effective rate of the study group (96.67%) was significantly higher than that of the controlgroup (76.67%) (χ2=5.192,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.218,P>0.05).Conclusion Clinical efficacy of mifepristone combined with gongliuxiao was better than the single use of mifepristone,and adverse reaction rate was low.It was worthy of clinical use.%目的：探讨米非司酮联合宫瘤消胶囊治疗子宫肌瘤的临床疗效。方法将60例子宫肌瘤患者按照数字表法随机分为研究组和对照组，各30例，其中研究组采用米非司酮联合宫瘤消胶囊治疗，而对照组则给予米非司酮单独治疗，治疗3个月后，比较2组患者之间的临床疗效及不良反应发生情况。结果在治疗后，研究组子宫（13.21±5.38）cm3及肌瘤体积（1.50±1.21）cm3均较对照组明显缩小（t=4.987、3.388，P<0.05）。研究组的治疗总有效率（96.67%）均明显高于对照组（76.67%）（χ2=5.192，P<0.05）。2组患者的不良反应发生率比较差异无统计学意义（χ2=0.218，P>0.05）。结论米非司酮联合宫瘤消胶囊治疗子宫肌瘤的临床疗效优于单用米非司酮，不良反应发生率低，值得临床推广使用。